Pfizer Inc. (PFE)

NYSE: PFE · Real-Time Price · USD
25.32
+0.28 (1.12%)
At close: Jul 2, 2025, 4:00 PM
25.23
-0.09 (-0.36%)
After-hours: Jul 2, 2025, 7:59 PM EDT
1.12%
Market Cap 143.95B
Revenue (ttm) 62.46B
Net Income (ttm) 7.88B
Shares Out 5.69B
EPS (ttm) 1.38
PE Ratio 18.31
Forward PE 8.99
Dividend $1.72 (6.79%)
Ex-Dividend Date Jul 25, 2025
Volume 36,771,498
Open 25.13
Previous Close 25.04
Day's Range 25.03 - 25.36
52-Week Range 20.92 - 31.54
Beta 0.49
Analysts Hold
Price Target 29.92 (+18.17%)
Earnings Date Aug 5, 2025

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]

Sector Healthcare
Founded 1849
Country United States
Stock Exchange NYSE
Ticker Symbol PFE
Full Company Profile

Financial Performance

In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $29.92, which is an increase of 18.17% from the latest price.

Price Target
$29.92
(18.17% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth

The Cannabis Lighting Market is set to grow at a CAGR of 7.6% during the forecast period, driven by rising medical cannabis use and cultivation. Key players like Pfizer are entering the market. LED li...

1 day ago - GlobeNewsWire

House committee subpoenas Pfizer executive in probe of alleged COVID vaccine delay, CNN reports

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an allegation that clinical testing related to the company's COVID-19 vaccine...

2 days ago - Reuters

XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

CAMBRIDGE, Mass. , June 29, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaki...

3 days ago - PRNewsWire

Pfizer's bleeding disorder therapy meets main goal in patients with certain antibodies

Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies.

6 days ago - Reuters

Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents liv...

6 days ago - Business Wire

Pfizer Could Be The Turnaround Story In The Pharmaceutical Space

Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep ...

7 days ago - Seeking Alpha

Pfizer Declares Third-Quarter 2025 Dividend

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to...

7 days ago - Business Wire

Don't Sleep On Pfizer: The Turnaround Is Just Getting Started

Despite a revenue miss, Pfizer's Q1 earnings crushed estimates due to aggressive, structural cost-cutting, signaling a powerful shift towards operational and margin excellence. Management is expanding...

7 days ago - Seeking Alpha

17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars

I use YCharts' Value Score and Ben Graham Formula Value All Stars, or GASV, to identify large-cap stocks offering strong value and dividend safety. Seventeen out of twenty-four "safer" lowest-priced D...

7 days ago - Seeking Alpha

Top stock price forecast: Plug Power, Uber, and Pfizer

The US stock market bounced back on Tuesday after the truce between Iran and Israel. The Dow Jones, Nasdaq 100, and S&P 500 indices jumped by over 1%, and the bullish momentum continued in the futures...

Other symbols: PLUGUBER
7 days ago - Invezz

Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, ...

7 days ago - Business Wire

10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June

Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...

Other symbols: BBYBMYCAGEQRETRFRTKEY
8 days ago - Seeking Alpha

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

9 days ago - CNBC Television

The Dark Side Of Dividend Growth Investing

Dividend growth investing is a powerful way to compound wealth and set yourself up for financial independence. However, it also has some real drawbacks. I share 3 aspects of the dark side of dividend ...

Other symbols: ETLEGOTWBAWPCXIFR
11 days ago - Seeking Alpha

I'm Buying Dividend Giants At Huge Discounts

Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o...

12 days ago - Seeking Alpha

Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out

Pfizer's >7% dividend yield is attractive, but faces significant risk due to political, regulatory, and business headwinds impacting revenue and profitability. Major threats include U.S. healthcare po...

12 days ago - Seeking Alpha

Pfizer: An Offensive Play For A Bear Market

The market has become overly pessimistic on Pfizer, focusing on the patent cliff while ignoring the defensive cash flows and offensive catalysts. This has created a classic value opportunity. A fortre...

12 days ago - Seeking Alpha

RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports

U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, c...

Other symbols: MRKSNY
14 days ago - Reuters

RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury

A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used...

Other symbols: MRKSNY
14 days ago - CNBC

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Other symbols: MRKXRAY
14 days ago - Benzinga

50% Off - 2 Dividend Gems With Huge Income And Growth Potential

Investing capital means balancing risk, goals, and timing, especially when markets face uncertainty and shifting global dynamics. I focus on long-term value and income. I highlight two undervalued opp...

Other symbols: REXR
14 days ago - Seeking Alpha

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

Two Democratic lawmakers on Tuesday pressed five of the nation's largest pharmaceutical companies about their low tax bills and whether they support extending massive tax cuts for the industry in the ...

Other symbols: ABBVAMGNJNJMRK
15 days ago - CNBC

Two Alternatives For A Potential $5000 Monthly Income

Traditionally, a large portion of equity returns has come from two factors - reinvested dividends and compounding. We present two income-focused approaches: a fund-based portfolio for hands-off invest...

18 days ago - Seeking Alpha

Why Apple, Microsoft, Pfizer and other U.S. multinational corporations set up shop in Ireland

U.S. firms remain attracted to Ireland's strong business environment built on favorable tax treatment of intellectual property.

Other symbols: AAPLMSFT
20 days ago - CNBC

5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen

Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YC...

22 days ago - Seeking Alpha